Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548437 | 0.82 | KCNJ1 (0.42) | — | |
| SCHEMBL4548441 | 0.80 | CRBN (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10312549 | 0.79 | HDAC1 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4548435 | 0.77 | HCAR2 (0.41) | — | |
| SCHEMBL30993007 | 0.69 | HDAC1 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14164231 | 0.65 | CKS1B (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4525033 | 0.60 | PREP (0.34) | — | |
| SCHEMBL2408981 | 0.60 | KDM4E (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2408983 | 0.60 | KDM4E (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2144162 | 0.59 | NFE2L2 (0.54) | KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HDAC3 1144/4885HDAC4 1672/4885HDAC1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.